Ranitidine or dobutamine alone or combined has no effect on gastric intramucosal-arterial PCO(2) difference after cardiac surgery

Intensive Care Med. 2000 Jan;26(1):45-51. doi: 10.1007/s001340050010.

Abstract

Objective: To test the hypothesis that ranitidine, either alone or in combination with dobutamine, modifies the gastric intramucosal-arterial PCO(2) difference.

Design: Full factorial design (double-blinded for ranitidine).

Setting: Intensive Care Unit of a university hospital.

Patients: Sixty-four haemodynamically stable coronary artery bypass surgery patients.

Interventions: Ranitidine (150 mg preoperatively per os and 50 mg intravenously postoperatively) and dobutamine (4 micro g. kg(-1). min(-1) for 3 h postoperatively) were administered in four randomised groups of patients: preoperative and postoperative ranitidine, either alone (n = 15) or in combination with dobutamine (n = 17), dobutamine alone (n = 15) or neither ranitidine nor dobutamine (n = 17).

Measurements and results: Gastric intramucosal-arterial PCO(2) difference was measured during the first 5 postoperative hours. No differences in the postoperative pattern of gastric intramucosal-arterial PCO(2) difference were found among the groups.

Conclusions: Ranitidine and dobutamine have no effect on the gastric tonometry results on intramucosal-arterial PCO(2) difference after uncomplicated cardiac surgery. Hence, the routine use of H(2)-antagonists for gastrointestinal tonometry is not warranted. Our results must be limited to results obtained by tonometry; they do not allow any conclusions on the effects of these drugs on splanchnic blood flow or its distribution.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Agonists / administration & dosage
  • Adrenergic beta-Agonists / therapeutic use*
  • Adult
  • Analysis of Variance
  • Carbon Dioxide / blood*
  • Coronary Artery Bypass*
  • Dobutamine / administration & dosage
  • Dobutamine / therapeutic use*
  • Double-Blind Method
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Gastric Mucosa / drug effects*
  • Gastric Mucosa / metabolism
  • Hemodynamics
  • Histamine H2 Antagonists / administration & dosage
  • Histamine H2 Antagonists / therapeutic use*
  • Humans
  • Hydrogen-Ion Concentration
  • Male
  • Middle Aged
  • Postoperative Period
  • Ranitidine / administration & dosage
  • Ranitidine / therapeutic use*

Substances

  • Adrenergic beta-Agonists
  • Histamine H2 Antagonists
  • Carbon Dioxide
  • Dobutamine
  • Ranitidine